Publication: Research - peer-review › Journal article – Annual report year: 2012
The entire substrate translocation pathway in the human GABA transporter (GAT-1) was explored for the endogenous substrate GABA and the anti-convulsive drug tiagabine. Following a steered molecular dynamics (SMD) approach, in which a harmonic restraining potential is applied to the ligand, dissociation and re-association of ligands were simulated revealing events leading to substrate (GABA) translocation and inhibitor (tiagabine) mechanism of action. We succeeded in turning the transporter from the outward facing occluded to the open-to-out conformation, and also to reorient the transporter to the open-to-in conformation. The simulations are validated by literature data and provide a substrate pathway fingerprint in terms of which, how, and in which sequence specific residues are interacted with. They reveal the essential functional roles of specific residues, e.g. the role of charged residues in the extracellular vestibule including two lysines (K76 (TM1) and K448 (TM10)) and a TM6-triad (D281, E283, and D287) in attracting and relocating substrates towards the secondary/interim substrate-binding site (S2). Likewise, E101 is highlighted as essential for the relocation of the substrate from the primary substrate-binding site (S1) towards the cytoplasm.
|Citations||Web of Science® Times Cited: 4|
- BIOLOGY, AMINOBUTYRIC-ACID TRANSPORTER, TRANSMEMBRANE DOMAIN-I, FREE-ENERGY DIFFERENCES, NEUROTRANSMITTER TRANSPORTERS, BACTERIAL HOMOLOG, HIGH-AFFINITY, RAT-BRAIN, SUBSTRATE-BINDING, DRUG TARGETS, ION-BINDING
No data available